3 results about "Virus free" patented technology

The application discloses a rhabdovirus-free Sf9 cell screening method of double pretreated conditioned medium, relates to the technical field of biology, and obtains the rhabdovirus-free Sf9 cell by double pretreatment of the conditioned medium through cross-flow filtration and beta-propiolactone inactivation and hydrolysis, and combination of single cell cloning screening. The method realizes efficient virus interception and high-activity retention of nutritional factors, the single cell cloning formation rate is greater than 40%, and is suitable for virus-free cell bank construction and biological product production.

The present application relates to the technical field of medicinal plant tissue culture, in particular to a rapid virus-free cloning method and reagent combination for medicinal plant tissue culture. The method comprises the following steps: pretreatment and disinfection of explants, precise virus elimination, preparation of dynamic adaptive medium, rapid propagation, real-time high-throughput detection of virus-free, seedling raising and transplanting, etc. The reagent combination comprises a multifunctional degradable reagent kit, intelligent response type nano disinfection microcapsules, special reagents such as composite virus elimination liquid, etc. The virus elimination rate is greater than or equal to 95%, the survival rate of explants is greater than or equal to 90%, the propagation cycle is shortened by 30%, the detection time is less than or equal to 2 hours, the survival rate of transplanting is greater than or equal to 85%, and the degradation rate of reagents is greater than or equal to 90%. The present application is suitable for herbaceous, woody and liana medicinal plants of the families of Araliaceae, Eucommiaceae, Orchidaceae and Campanulaceae, etc., can realize stable virus elimination and propagation effect, significantly improve the virus-free cloning efficiency and seedling quality, and meet the green production demand.

This invention provides a method for preparing a composite solution of sodium hyaluronate and recombinant type III humanized collagen. The invention utilizes artificial screening and design to obtain recombinant type III humanized collagen COL3A1-QS-1, which is highly efficient in secretion and expression in Pichia pastoris. Compared with animal-derived collagen, it has advantages such as uniform molecular weight, high purity, no risk of viral transmission, low rejection reaction, and high bioactivity. Sodium hyaluronate absorbs water and swells into a gel, physically filling tissue volume loss and thus achieving the effect of filling wrinkles and smoothing fine lines. Recombinant type III humanized collagen provides a scaffold and favorable microenvironment for cells, promoting cell adhesion, proliferation, growth, migration, and support for cells and tissues. The composite solution of sodium hyaluronate and recombinant type III humanized collagen prepared from these two components stimulates collagen production by improving the local internal environment, thereby improving superficial wrinkles.